JP5190272B2 - Hiv阻害性2(4−シアノフェニルアミノ)ピリミジン誘導体 - Google Patents
Hiv阻害性2(4−シアノフェニルアミノ)ピリミジン誘導体 Download PDFInfo
- Publication number
- JP5190272B2 JP5190272B2 JP2007552651A JP2007552651A JP5190272B2 JP 5190272 B2 JP5190272 B2 JP 5190272B2 JP 2007552651 A JP2007552651 A JP 2007552651A JP 2007552651 A JP2007552651 A JP 2007552651A JP 5190272 B2 JP5190272 B2 JP 5190272B2
- Authority
- JP
- Japan
- Prior art keywords
- formula
- compounds
- compound
- hiv
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 CC1(C=C(C)C(*c2nc(Nc(cc3)ccc3C#N)nc(N)c2Br)=C(C)C1)C#N Chemical compound CC1(C=C(C)C(*c2nc(Nc(cc3)ccc3C#N)nc(N)c2Br)=C(C)C1)C#N 0.000 description 4
- KFQCZMYZHMOKLP-UHFFFAOYSA-N NC(C=C1)=CCC1C#N Chemical compound NC(C=C1)=CCC1C#N KFQCZMYZHMOKLP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Description
の化合物、それらの製薬学的に許容され得る付加塩及び立体化学異性体形態物に関する。
エンスルホネートのような有効な離脱基をもつ他の反応物も使用することができる。第四級アミンは正に帯電した窒素を有する。製薬学的に許容され得る対イオンはクロロ、ブロモ、ヨード、トリフルオロアセテート及びアセテートを包含する。選択するべき対イオンはイオン交換樹脂を使用して導入することができる。
ヒドロフラン(THF)、1,4−ジオキサン、プロピレングリコールモノメチルエーテルのようなエーテル、のような適当な溶媒中で実施される。これらの反応は適当な酸(例えば、カンファースルホン酸)及び適当な溶媒(例えば、テトラヒドロフラン又はアルコール(例えば、エタノール、1−又は2−プロパノール)のような)の量を添加するかあるいは、アルカノール(エタノール、1−又は2−プロパノールのような)中に溶解された酸性化溶媒(例えば、塩酸)を使用することにより得ることができる酸条件下で実施することができる。
物に転化させ、次に、例えば、選択的結晶化又はクロマトグラフィー法(例えば、液体クロマトグラフィー等の方法)によりジアステレオマー塩又は化合物の該混合物を物理的に分離し、そして最後に前記の分離したジアステレオマー塩又は化合物を対応するエナンチオマーに転化させる工程により、ラセミ混合物から得ることができる。介入する反応が立体特異的に起ると仮定すると、純粋な立体化学的異性体形態物はまた、適当な中間体及び出発物質の純粋な立体異性体形態物から得ることができる。
−6アルキルであり、各Rは好ましくはメチルである。この反応は還流温度のような高温でアルカリ金属アルコキシド、例えばナトリウムメトキシドのような強塩基の存在下で、適当な溶媒、例えばメタノールのようなアルコール中で実施することができる。
い影響を有するのみである。
シエチルにより置換されているエーテルである。
定性:Lc面積%:>95%.
定性:Lc面積%:>98%
定性:Lc面積%:95.3%
定性:Lc重量%:98.8%.
定性:GC面積%:100%
定性:Gc:100%P。
定性:Lc面積%:77%生成物。
定性:Lc面積%:81%
定性:Lc面積%:98%
定性:Lc面積%:62.3%中間体K及び
24.9%対応するSO2−生成物
定性:Lc面積%:34%P。
定性:Lc面積%:98%。
カプセル
錠剤コアの調製
1000gの化合物1、2850gのラクトース及び1000gのデンプンの混合物を十分混合し、その後、25gのドデシル硫酸ナトリウム及び50gのポリビニルピロリドンの溶液(約1000mlの水中)で湿らせる。湿った粉末混合物をふるい、乾燥し、再度ふるう。次に500gの微細結晶セルロース及び75gの水素化植物油を添加する。全体を十分混合し、打錠すると、有効成分を各100mg含んでなる10,000錠を与える。
10gのメチルセルロースの溶液(75mlの変性エタノール中)に5gのエチルセルロースの溶液(150mlのジクロロメタン中)を添加する。次に75mlのジクロロメタン及び2.5mlの1,2,3−プロパントリオールを添加する。10gのポリエチレングリコールを融解し、75mlのジクロロメタン中に溶解する。後者の溶液を前者に添
加し、次に2.5gのマグネシウムオクタデカノエート、5gのポリビニルピロリドン及び30mlの濃厚色素懸濁物を添加し、全体をホモジナイズする。錠剤コアをコート装置中でこのようにして得られた混合物でコートする。
薬剤耐性HIV株の発生増加のために、本発明の化合物を幾つかの突然変異体を隠蔽する臨床的に単離されたHIV株に対するそれらの効力を試験した。これらの突然変異体は逆転写酵素インヒビターに対する耐性を伴い、例えばAZT及びデラビルジンのような近年市販されている薬剤に種々の度合いの表現型交差耐性を示すウイルスをもたらす。
Claims (6)
- 製薬学的に許容され得る担体及び、有効成分として治療的に有効量の請求項1に記載の化合物を含んでなる製薬学的組成物。
- 有効成分としての請求項1に記載の化合物及び担体を均一に混合する工程を含んでなる請求項2記載の組成物を調製する方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05100521 | 2005-01-27 | ||
EP05100521.3 | 2005-01-27 | ||
PCT/EP2006/050490 WO2006079656A1 (en) | 2005-01-27 | 2006-01-27 | Hiv inhibiting 2-( 4-cyanophenylamino) pyrimidine derivatives |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012274674A Division JP2013082722A (ja) | 2005-01-27 | 2012-12-17 | Hiv阻害性2(4−シアノフェニルアミノ)ピリミジン誘導体 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2008528554A JP2008528554A (ja) | 2008-07-31 |
JP5190272B2 true JP5190272B2 (ja) | 2013-04-24 |
Family
ID=34938584
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2007552651A Expired - Fee Related JP5190272B2 (ja) | 2005-01-27 | 2006-01-27 | Hiv阻害性2(4−シアノフェニルアミノ)ピリミジン誘導体 |
JP2012274674A Pending JP2013082722A (ja) | 2005-01-27 | 2012-12-17 | Hiv阻害性2(4−シアノフェニルアミノ)ピリミジン誘導体 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012274674A Pending JP2013082722A (ja) | 2005-01-27 | 2012-12-17 | Hiv阻害性2(4−シアノフェニルアミノ)ピリミジン誘導体 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20090124644A1 (ja) |
EP (2) | EP1853568B1 (ja) |
JP (2) | JP5190272B2 (ja) |
CN (1) | CN101107234B (ja) |
AT (1) | ATE523498T1 (ja) |
AU (1) | AU2006208778B2 (ja) |
BR (1) | BRPI0607214B8 (ja) |
CA (1) | CA2599228C (ja) |
ES (1) | ES2373820T3 (ja) |
MX (1) | MX2007009015A (ja) |
RU (1) | RU2403245C2 (ja) |
WO (1) | WO2006079656A1 (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7935711B2 (en) * | 2005-02-18 | 2011-05-03 | Tibotec Pharmaceuticals Ltd. | HIV inhibiting 2-(4-cyanophenylamino) pyrimidine oxide derivatives |
TW200734321A (en) * | 2005-10-27 | 2007-09-16 | Teijin Pharma Ltd | Benzo [b] thiophen derivatives and a process for producing benzo [b] thiophen derivatives |
CA2674178C (en) * | 2006-12-29 | 2015-11-10 | Tibotec Pharmaceuticals Ltd. | Hiv inhibiting 6-substituted pyrimidines |
AU2007341228B2 (en) * | 2006-12-29 | 2013-04-18 | Janssen Sciences Ireland Uc | HIV inhibiting 5,6-substituted pyrimidines |
UA106972C2 (uk) * | 2009-06-22 | 2014-11-10 | Емк'Юр Фармас'Ютікалз Лімітед | Спосіб синтезу діарилпіримідинового ненуклеозидного інгібітора зворотної транскриптази |
US8153790B2 (en) | 2009-07-27 | 2012-04-10 | Krizmanic Irena | Process for the preparation and purification of etravirine and intermediates thereof |
CN102718720B (zh) * | 2012-07-04 | 2015-01-07 | 宁波九胜创新医药科技有限公司 | 4-[(4,6-二氯-2-嘧啶基)氨基]苯腈的制备方法 |
CN102731414B (zh) * | 2012-07-04 | 2014-11-26 | 宁波九胜创新医药科技有限公司 | 4-[(4-氯-2-嘧啶基)氨基]苯腈的制备方法 |
WO2014072419A1 (en) | 2012-11-08 | 2014-05-15 | Universiteit Antwerpen | Novel anti-hiv compounds |
RU2729792C1 (ru) * | 2019-07-29 | 2020-08-12 | Акционерное общество "Научно-производственное объединение "ДОМ ФАРМАЦИИ" | Способы повышения растворимости лекарственного средства на основе пиримидинового производного бензофенона |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3459731A (en) | 1966-12-16 | 1969-08-05 | Corn Products Co | Cyclodextrin polyethers and their production |
SK67298A3 (en) | 1995-11-23 | 1998-11-04 | Janssen Pharmaceutica Nv | Solid mixtures of cyclodextrins prepared via melt-extrusion |
NZ511116A (en) * | 1998-11-10 | 2003-08-29 | Janssen Pharmaceutica Nv | HIV replication inhibiting pyrimidines |
US20050239054A1 (en) * | 2002-04-26 | 2005-10-27 | Arimilli Murty N | Method and compositions for identifying anti-HIV therapeutic compounds |
-
2006
- 2006-01-27 WO PCT/EP2006/050490 patent/WO2006079656A1/en active Application Filing
- 2006-01-27 RU RU2007132179/04A patent/RU2403245C2/ru active
- 2006-01-27 JP JP2007552651A patent/JP5190272B2/ja not_active Expired - Fee Related
- 2006-01-27 EP EP06707872A patent/EP1853568B1/en active Active
- 2006-01-27 AT AT06707872T patent/ATE523498T1/de not_active IP Right Cessation
- 2006-01-27 ES ES06707872T patent/ES2373820T3/es active Active
- 2006-01-27 CA CA2599228A patent/CA2599228C/en not_active Expired - Fee Related
- 2006-01-27 US US11/813,772 patent/US20090124644A1/en not_active Abandoned
- 2006-01-27 AU AU2006208778A patent/AU2006208778B2/en not_active Ceased
- 2006-01-27 BR BRPI0607214A patent/BRPI0607214B8/pt not_active IP Right Cessation
- 2006-01-27 EP EP11177764A patent/EP2388249A1/en not_active Ceased
- 2006-01-27 MX MX2007009015A patent/MX2007009015A/es active IP Right Grant
- 2006-01-27 CN CN2006800031094A patent/CN101107234B/zh not_active Expired - Fee Related
-
2012
- 2012-12-17 JP JP2012274674A patent/JP2013082722A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2006079656A1 (en) | 2006-08-03 |
RU2007132179A (ru) | 2009-03-10 |
ES2373820T3 (es) | 2012-02-09 |
AU2006208778B2 (en) | 2012-08-09 |
US20090124644A1 (en) | 2009-05-14 |
JP2008528554A (ja) | 2008-07-31 |
AU2006208778A1 (en) | 2006-08-03 |
ATE523498T1 (de) | 2011-09-15 |
CN101107234B (zh) | 2013-06-19 |
BRPI0607214B8 (pt) | 2021-05-25 |
BRPI0607214A2 (pt) | 2009-08-18 |
EP1853568A1 (en) | 2007-11-14 |
EP1853568B1 (en) | 2011-09-07 |
BRPI0607214B1 (pt) | 2019-09-10 |
RU2403245C2 (ru) | 2010-11-10 |
CA2599228A1 (en) | 2006-08-03 |
JP2013082722A (ja) | 2013-05-09 |
CN101107234A (zh) | 2008-01-16 |
CA2599228C (en) | 2014-05-13 |
EP2388249A1 (en) | 2011-11-23 |
MX2007009015A (es) | 2007-09-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5190272B2 (ja) | Hiv阻害性2(4−シアノフェニルアミノ)ピリミジン誘導体 | |
US10072015B2 (en) | HIV inhibiting bicyclic pyrimidine derivatives | |
JP5247154B2 (ja) | Hiv阻害性2−(4−シアノフェニルアミノ)ピリミジンオキシド誘導体 | |
RU2410379C2 (ru) | 5-замещенные пиримидины, ингибирующие вич | |
JP5118978B2 (ja) | Hiv阻害2−(4−シアノフェニル)−6−ヒドロキシルアミノピリミジン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090115 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120214 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120514 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120523 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120614 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120621 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120717 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120814 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121217 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20121227 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130122 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20130128 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20160201 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5190272 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |